---
title: "SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: References"
description: "Reference list for the formulary evidence report on SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency. 72 cited documents."
canonical: "https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/references"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: References

<a id="references"></a>

## 5 References

1. [Abdelmalak et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3751427/)
2. [Aynsley-Green et al. (1984)](https://pubmed.ncbi.nlm.nih.gov/6429437/)
3. [Barshop et al. (2004)](https://pubmed.ncbi.nlm.nih.gov/15464428/)
4. [Berendzen et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16725381/)
5. [Bertini et al. (2023)](https://link.springer.com/article/10.1186/s13023-023-02945-6)
6. [Betesh-Abay et al. (2026)](https://cris.bgu.ac.il/en/publications/pyruvate-dehydrogenase-complex-deficiency-a-review-of-treatments-/)
7. [Buajitti et al. (2022)](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0265744)
8. [Byrd et al. (1989)](https://pubmed.ncbi.nlm.nih.gov/2501097/)
9. [Calcutt et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2741559/)
10. [Cohen et al. (2018)](https://link.springer.com/article/10.1186/s13023-018-0949-5)
11. [Coude et al. (1978)](https://pubmed.ncbi.nlm.nih.gov/714110/)
12. [DeBrosse et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/23021068/)
13. [FDA complete response letter (2025)](https://download.open.fda.gov/crl/CRL_NDA218679_20250827.pdf)
14. [FDA Orphan Drug Designations and Approvals (1990)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=45290)
15. [Ganetzky et al. (2021)](https://www.ncbi.nlm.nih.gov/books/NBK571223/)
16. [Han et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18206410/)
17. [Harada et al. (1996)](https://pubmed.ncbi.nlm.nih.gov/8656986/)
18. [James and Stacpoole (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5558523/)
19. [James et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5274567/)
20. [Karissa et al. (2022)](https://www.frontierspartnerships.org/journals/british-journal-of-biomedical-science/articles/10.3389/bjbs.2022.10382/full)
21. [Kaufmann et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16476929/)
22. [Kossoff et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5983110/)
23. [Kuroda et al. (1986)](https://pubmed.ncbi.nlm.nih.gov/3099068/)
24. [Langaee et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29641284/)
25. [Madsen et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42341672/)
26. [Mangal et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5967850/)
27. [Marchet et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40087083/)
28. [McCormick et al. (1985)](https://pubmed.ncbi.nlm.nih.gov/4050860/)
29. [Merkevicius et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13337232/)
30. [Morten et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/10449128/)
31. [Naito et al. (1989)](https://pubmed.ncbi.nlm.nih.gov/2751069/)
32. [Patel et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4003492/)
33. [Pfeffer et al. (2021)](https://www.cochrane.org/evidence/CD004426_treatment-mitochondrial-disorders)
34. [Remes et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13370984/)
35. [Santos Gonzalez et al. (2024)](https://link.springer.com/article/10.1186/s13023-024-03462-w)
36. [Saol Therapeutics](https://saolrx.com/pipeline)
37. [Saol Therapeutics and InformedDNA (2022)](https://saolrx.com/saol-therapeutics-and-informeddna-partner-to-offer-genetic-counseling-to-patients-with-rare-mitochondrial-disease/)
38. [Saol Therapeutics clinical milestones announcement (2025)](https://saolrx.com/saol-therapeutics-announces-major-clinical-milestones-across-multiple-development-programs/)
39. [Saol Therapeutics complete response letter announcement (2025)](https://www.prnewswire.com/news-releases/saol-therapeutics-receives-complete-response-letter-from-fda-for-sl1009-dca-for-the-treatment-of-pyruvate-dehydrogenase-complex-deficiency-pdcd-302548522.html)
40. [Saol Therapeutics expanded access program policy](https://saolrx.com/expanded-access-program-policy/)
41. [Saol Therapeutics Fast Track designation announcement (2024)](https://saolrx.com/saol-therapeutics-receives-fast-track-designation-for-treatment-of-rare-mitochondrial-disease-pyruvate-dehydrogenase-complex-deficiency-pdcd/)
42. [Saol Therapeutics NDA acceptance announcement (2025)](https://saolrx.com/saol-therapeutics-announces-fda-acceptance-of-new-drug-application-for-sl1009-for-treatment-of-pyruvate-dehydrogenase-complex-deficiency/)
43. [Saol Therapeutics NDA resubmission acceptance announcement (2026)](https://www.prnewswire.com/news-releases/saol-therapeutics-announces-the-acceptance-of-resubmission-of-sl1009-dca-by-the-fda-with-pdufa-date-of-dec-30-2026-302836586.html)
44. [Saol Therapeutics NDA resubmission announcement (2026)](https://saolrx.com/saol-therapeutics-resubmits-the-new-drug-application-for-sl1009-dca-for-the-treatment-of-pyruvate-dehydrogenase-complex-deficiency-pdcd-an-ultra-rare-disease/)
45. [Saol Therapeutics NDA submission announcement (2024)](https://saolrx.com/saol-therapeutics-announces-submission-of-new-drug-application-nda-to-the-u-s-fda-for-sl1009/)
46. [Saol Therapeutics Type A meeting announcement (2025)](https://saolrx.com/saol-therapeutics-has-been-granted-a-type-a-meeting-with-the-fda-to-determine-the-path-forward-for-sl1009-in-pyruvate-dehydrogenase-complex-deficiency-pdcd/)
47. [Saol Therapeutics UMDF Mitochondrial Medicine 2025 poster announcement (2025)](https://saolrx.com/saol-therapeutics-announces-poster-presentation-at-the-umdf-mitochondrial-medicine-2025-conference/)
48. [Savvidou et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1111/ene.16283)
49. [Savvidou et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13089191/)
50. [Savvidou et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13445312/)
51. [Schofield et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40490132/)
52. [Shin et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28918066/)
53. [Shroads et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2613565/)
54. [Shroads et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3786668/)
55. [Shroads et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4276489/)
56. [Sofou (2013)](https://pubmed.ncbi.nlm.nih.gov/23529909/)
57. [Sofou et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5306430/)
58. [Stacpoole and Dorsey (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10563500/)
59. [Stacpoole et al. (1997)](https://pmc.ncbi.nlm.nih.gov/articles/PMC1717417/)
60. [Stacpoole et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16651305/)
61. [Stacpoole et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3777225/)
62. [Stacpoole et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6587967/)
63. [Stacpoole et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31208525/)
64. [Stacpoole et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12450258/)
65. [Stanford Health Care](https://stanfordhealthcare.org/trials/t/NCT02616484.html)
66. [Starosta et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11578067/)
67. [Tóth et al. (1993)](https://pubmed.ncbi.nlm.nih.gov/8355121/)
68. [UMDF and MitoAction (2023)](https://umdf.org/wp-content/uploads/2023/12/PDCD_Report_Final.pdf)
69. [United Mitochondrial Disease Foundation](https://umdf.org/pdcd/)
70. [University of Pennsylvania faculty bibliography](https://www.med.upenn.edu/apps/faculty/index.php/g275/p8141835)
71. [Verma et al. (2024)](https://onlinelibrary.wiley.com/doi/10.1002/mgg3.2283)
72. [Zhao et al. (2024)](https://link.springer.com/article/10.1186/s13023-024-03289-5)

## Related pages
- [SL1009 (sodium dichloroacetate): Pyruvate dehydrogenase complex deficiency](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency) · [Markdown](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency.md)
- [SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: Terms and abbreviations](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/terms-and-abbreviations.md)
- [SL1009 (sodium dichloroacetate): Pyruvate dehydrogenase complex deficiency](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/executive-summary) · [Markdown](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/executive-summary.md)
- [SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: Product information and disease description](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/product-information-and-disease-description.md)
- [SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: Clinical evidence](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/clinical-evidence.md)
- [SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: Economic information and modeling report](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/economics) · [Markdown](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/economics.md)
- [SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: prevalence by geography](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/prevalence) · [Markdown](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/prevalence.md)
- [SL1009 (sodium dichloroacetate) in Pyruvate dehydrogenase complex deficiency: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/cost-effectiveness-analyses.md)
